Dopaminergic but not glutamatergic neurotransmission is increased in the striatum after selective cyclooxygenase-2 inhibition in normal and hemiparkinsonian rats

Basic and Clinical Pharmacology and Toxicology

Volumn 103, Issue 4, 2008, Pages 293-296

  Fathi Moghaddam, Hadi ^c   Ardestani, Mehdi Shafiee ^a   Saffari, Mostafa ^b   Navidpour, Latifeh ^a   Shafiee, Abbas ^a   Rahmim, Arman ^d  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ARYL 5 (4 METHYLSULFONYLPHENYL)IMIDAZOLE DERIVATIVE; 5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; GLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; DRUG ACTIVITY; DRUG EFFECT; ENZYME INHIBITION; MALE; NERVE CELL LESION; NEUROTRANSMISSION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA;

ANIMALS; CORPUS STRIATUM; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUTAMIC ACID; MALE; MICRODIALYSIS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PYRAZOLES; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SULFONAMIDES; SYNAPTIC TRANSMISSION;

RATTUS;

EID: 52049085762     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00295.x     Document Type: Article

References (15)

1. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory and degenerative brain disease. J Neuropathol Exp Neurol 2004 63 : 901 10.
2. Shafiee Ardestani M, Fathi Moghaddam H, Hemmati AA. Effects of Aspirin and Celecoxib on rigidity in a rat model of Parkinson's disease. J Biol Sci 2007 21 : 3853 8.
3. Teismann P, Tieu K, Choi DK, Wu DC, Naini A, Hunot S et al. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci USA 2003 100 : 5473 8.
4. Tyurina YY, Kapralov AA, Jiang J, Borisenko GG, Potapovich AI, Sorokin A et al. Oxidation and cytotoxicity of 6-OHDA are mediated by reactive intermediates of COX-2 overexpressed in PC12 cells. Brain Res 2006 1093 : 71 82.
5. Chen C, Bazan NG. Lipid signaling: sleep, synaptic plasticity, and neuroprotection. Prostaglandins Other Lipid Mediat 2005 77 : 65 76.
6. Cole-Edwards KK, Bazan NG. Lipid signaling in experimental epilepsy. Neurochem Res 2005 30 : 847 53.
7. Allain H, Bentue'-Ferrer DL, Akwa Y. Disease-modifying drugs and Parkinson's disease. Prog Neurobiol 2008 84 : 25 39
8. Navidpour L, Shadnia H, Shafaroodi H, Amini M, Dehpour AR, Shafiee A. Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5- diarylimidazoles as selective COX-2 inhibitors. Bioorg Med Chem 2007 15 : 1976 82.
9. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA, 1997.
10. Duran M, Alfonso B, Arias A. Determination of biogenic amines in rat brain dialysates by high performance liquid chromatography. J Liq Chromotogr Relat Technol 1998 21 : 2799 811.
11. Hao Y, Yang JY, Guo M, Wu CF, Wu MF. Morphine decreases extracellular levels of glutamate in the anterior cingulate cortex: an in vivo microdialysis study in freely moving rats. Brain Res 2005 1040 : 191 6.
12. Shafiee Ardestani M, Hasan M, Sadeghzadeh N. Effects of dexamethasone and betamethasone as COX-2 gene expression inhibitors on rigidity in a rat model of Parkinson's disease. Indian J Pharmacol 2007 39 : 235 9.
13. Katzung BG. Basic and Clinical Pharmacology. Appleton and Lange, New York, 2004 298 311, 577 and 643 6.
14. Riechman W, Hokin LE. Acetylcholine releases prostaglandins from brain slices incubated in vitro. J Neurochem 1987 49 : 1221 61.
15. Casper D, Yaparpalvi U, Rempel N, Werner P. Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro. Neurosci Lett 2000 289 : 201 4.